Skip to content

Grassley Leads Colleagues in Seeking Explanation, Urging Reconsideration of Changes to Kratom-Derived Scheduling

WASHINGTON – Senate Judiciary Committee Chairman Chuck Grassley (R-Iowa) and seven of his Republican colleagues are urging the Drug Enforcement Administration (DEA) and the Food and Drug Administration (FDA) to explain and reconsider changes to the emergency scheduling order for semi-synthetic, kratom-derived substances, including deadly 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl (MP).

Following a revised recommendation from FDA, the DEA in October issued an updated proposal that doubled the threshold originally established for 7-OH and removed MP from Schedule I of the Controlled Substances Act. DEA’s October decision would allow both chemicals to be present in over-the-counter kratom products at levels higher than those found naturally in the kratom plant. Prior to DEA’s updated proposal, Grassley, along with Sens. Susan Collins (R-Maine) and Mike Lee (R-Utah), had urged DEA and FDA to implement the agencies’ original scheduling order and permanently place all harmful kratom-derived substances into Schedule I.

“Kratom is a drug in any form with addictive properties, and we believe this combined threshold level for 7-OH and MP set by DEA is inappropriately high and unsound… If the administration’s goal is to remove all unsafe products from the shelves, particularly synthetic or enhanced kratom products, this order misses the mark,” the senators wrote.

“The psychoactive alkaloids of the kratom plant are potentially dangerous substances that should be treated with caution, particularly given the lack of adequate regulation on its products… The American people deserve peace of mind about what is sold on marketplace shelves and a public health system that makes sound regulatory decisions,” the senators continued.

Specifically, the senators are requesting DEA and FDA:

  • Provide Congress the scientific and medical evaluations the agencies relied on to set a higher threshold limit for 7-OH.
  • Explain how a higher threshold for 7-OH better protects American families than the original, lower threshold.
  • Reconsider the updated threshold level for 7-OH and place kratom substances containing any amount of MP in Schedule I.

Grassley is joined by Sens. Susan Collins (R-Maine), Rick Scott (R-Fla.), Mike Crapo (R-Idaho), Bill Cassidy (R-La.), Jerry Moran (R-Kan.), Shelley Capito (R-W.Va.) and Jim Risch (R-Idaho).

Read the full letter HERE. A fact sheet on kratom and the timeline for DEA’s proposed scheduling order is available HERE.

Background:

Kratom leaves contain two major psychoactive ingredients: mitragynine and 7-hydroxymitragynine (7-OH). These substances can be concentrated and chemically modified to produce extremely potent, semi-synthetic compounds – MP, MGM-15 and MGM-16. Kratom and kratom-derived substances are sold over the counter across the country, available to all age groups as “natural” energy boosters, mood lifters and pain relievers.

According to the FDA, known side effects of kratom include liver toxicity, seizures, substance use disorder and, in rare cases, death. According to the DEA, state health authorities have linked the use of 7-OH products and concentrated extracts to dependence, addiction, acute psychosis, slowed breathing, cardiac arrest and death.

Kratom-derived 7-OH has been identified as having a similar abuse potential to heroin or fentanyl and is known to be 13-times more potent than morphine. Other kratom-derived compounds, like MP, are known to be 20-times more potent than morphine.

-30-